Malignant astrocytomas are associated with poor prognosis and high morbidity and mortality rates despite intensive treatment. These tumors rarely metastasize into distant regions of the body; however, they are highly invasive into adjacent and distant regions of the normal brain, which renders them surgically and medically unmanageable and accounts for their fatal outcome.Invasion is a multistep process, which ultimately requires the cell to actively migrate through the ECM. Proper cell adhesion dynamics, involving the assembly and the disassembly of adhesion, is essential for the completion of the motility cycle. Rho-GTPases, mainly RhoA, Rac, and Cdc42, play a major role in the regulation of the processes that ultimately lead to cell migration. StarD13 is a RhoGAP that inhibits the function of RhoA and Cdc42.We first aimed at determining the role of RhoA in the progression of astrocytic tumors, a topic that is still controversial in the literature. Our results showed that RhoA plays a positive role in this aspect.Our current study also investigates the roles of RhoA, Rac1, and StarD13 in cell adhesion and cell migration. Our results showed that RhoA, Rac1, and StarD13 are essential for astrocytoma cell migration. Rac1 plays a role in the formation of focal complexes, which ultimately mature into focal adhesions under the action of RhoA. StarD13 plays a role in the inhibition of RhoA in focal complexes, a process that seems indispensible for astrocytoma cell migration. The incidence rate of primary malignant brain and central nervous system tumors is 6.4 cases per 100,000 person-years (Horner, et al., 2009). This rate of occurrence is higher in males than it is in females (7.6 compared to 5.4 per 100,000 person-years respectively).The lifetime risk of developing a primary malignant brain or a central nervous system tumor is 0.67% in males and 0.54% in females (Horner, et al., 2009). The chance of dying from a brain or a central nervous system tumor is 0.48% in males compared to 0.38% in females (Horner, et al., 2009).
ClassificationThe (CBTRUS, 2011;Louis, et al., 2007). Gliomas can either be low-grade or high-grade (malignant). Malignant gliomas are pathologically, histologically, and genetically heterogeneous tumors and they are known to be invasive (DeAngelis, 2001).
AstrocytomasAstrocytomas are gliomas that arise from astrocytes (Louis, et al., 2007). Based on the classification of the World Health Organization (WHO), astrocytomas are assigned into one of four prognostic grades: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma), with grades III and IV considered malignant (Louis, et al., 2007). Malignant astrocytomas are usually associated with a poor prognosis and high morbidity and mortality rates despite intensive treatment.The median survival time is 12 to 14 months for patients with glioblastoma and 2 to 5 years for patients with anaplastic astrocytoma (Wen & Kesari, 2008). For unclear reasons, malignant astrocyt...